Recent Updates
Recently added Catalysts
VKTX Positive Sentiment

VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial of weekly subcutaneous administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes

Friday, November 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the VANQUISH-2 trial, a Phase 3 study evaluating VK2735 for treating obesity in adults with Type 2 Diabetes. This trial is randomized, double-blind, and placebo-controlled, aiming to assess the efficacy of weekly subcutaneous administration. The focus on this demographic addresses a critical health concern.
Price reaction · baseline $37.27 (2025-11-06 close) · hit pre-market · 1 other VKTX headline(s) in the window, move may be shared
day 0 close
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • VK2735 is undergoing a Phase 3 trial, indicating advanced development.
  • The trial is randomized and double-blind, ensuring robust results.
  • Focus on obese or overweight adults with Type 2 Diabetes highlights a significant health issue.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

• About Management Board of Directors Careers
• Pipeline Overview VK2735 VK3019 VK2809 VK0214 VK5211 Publications
• Investors Overview Stock Information Stock Chart Historical Price Lookup News & Events Press Releases Webcasts SEC Filings Analyst Coverage Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition Shareholder Services Information Request E-mail Alerts Investor Relations Contacts Corporate Presentation
• Contact
• Management
• Board of Directors
• Careers
• Overview
• VK2735
• VK3019
• VK2809
• VK0214
• VK5211
• Publications
• Overview
• Stock Information Stock Chart Historical Price Lookup
• News & Events Press Releases Webcasts
• SEC Filings
• Analyst Coverage
• Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition
• Shareholder Services Information Request E-mail Alerts Investor Relations Contacts
• Corporate Presentation
• Stock Chart
• Historical Price Lookup
• Press Releases
• Webcasts
• Governance Highlights
• Mangement
• Board of Directors
• Committee Composition
• Information Request
• E-mail Alerts
• Investor Relations Contacts

Frequently Asked Questions

What is the VANQUISH-2 trial?

The VANQUISH-2 trial is a Phase 3 study evaluating VK2735 for obesity treatment in Type 2 Diabetes.

What type of trial design is used in VANQUISH-2?

The trial is randomized, double-blind, and placebo-controlled.

Who are the participants in the VANQUISH-2 trial?

The trial focuses on obese or overweight adults diagnosed with Type 2 Diabetes.

What is VK2735?

VK2735 is a therapeutic agent being tested for its efficacy in treating obesity in Type 2 Diabetes patients.

ShareAdd on Google
Tags: VKTX Viatris Investor Conferences Healthcare VK2735 Type 2 Diabetes obesity clinical trial
Last updated: Nov 7, 2025

Biotech snapshot

Cash runway
$502M liquidity · $42M/mo burn
~11 mo
Medium dilution risk
Lead asset
VK2735Phase 3
Weight Loss →

Catalyst track record

+53%
best trade around VKTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for VKTX.

See every catalyst's timing & PoA →